Can We Omit Systematic Biopsies in Men with a Positive MRI During Repeat Biopsies for Active Surveillance for Prostate Cancer? Results from the PRIAS Study

Background and objective This study evaluated the added value of systematic biopsies (SBx) in addition to targeted biopsies (TBx) for detecting upgrading during repeat biopsies on active surveillance (AS) using data from the Prostate Cancer Research International Active Surveillance study. Methods We analyzed repeat biopsies of men who underwent magnetic resonance imaging (MRI) and SBx at diagnosis, with or without TBx depending on the presence of an MRI lesion, had at least one positive (Prostate Imaging Reporting and Data System 3–5) follow-up MRI, and received both SBx + TBx at subsequent repeat biopsy. Upgrading compared with diagnostic biopsy was assessed for TBx only, SBx only, and both, using three definitions: any upgrading, upgrading to grade group (GG) ≥2 with cribriform growth or intraductal carcinoma (≥GG2+), and upgrading to ≥GG3. Cumulative incidences were calculated using each detection method as competing events. For upgrading ≥GG2+ detected by SBx only, the laterality relative to the MRI lesion was determined. Key findings and limitations We analyzed 650 repeat biopsies in 568 patients with a median follow-up of 3.0 yr (interquartile range = 1.8–4.3) for men still on AS. During available follow-up, any upgrading occurred in 238 biopsies (37%), of which 47 (7.2%) were detected by SBx only. Upgrading to ≥GG2+ and ≥GG3 was observed in 100 biopsies (16%) and 78 biopsies (12%), respectively, with SBx alone identifying 19 (3.0%) and 15 (2.3%) of these patients. At 6 yr, the cumulative incidence of ≥GG2+ upgrading was 27% (95% confidence interval [CI] = 21–32%), with 5.4% (95% CI = 2.9–9.1%) for upgrading detected exclusively by SBx. Three of the 19 cases with upgrading to ≥GG2+ detected by SBx only were located contralateral to the MRI lesion (0.5% of all biopsies). Limitations include the retrospective design, which may introduce selection and registration biases. Conclusions and clinical implications In men on AS who underwent diagnostic MRI with SBx (with or without TBx) and a positive follow-up MRI, SBx has limited added value during repeat biopsies, particularly for contralateral sampling, supporting a targeted and perilesional biopsy approach.

Authors

Institutions

Publication Details

Journal
European Urology Open Science
Published
2026-10-13
DOI
https://doi.org/10.1016/j.euros.2026.09.006
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Can We Omit Systematic Biopsies in Men with a Positive MRI During Repeat Biopsies for Active Surveillance for Prostate Cancer? Results from the PRIAS Study

C. Marenghi, Sebastiaan Remmers, Monique J. Roobol, Karl H. Tully et al.
European Urology Open Science
Prostate Cancer Diagnosis and Treatment
article

Can We Omit Systematic Biopsies in Men with a Positive MRI During Repeat Biopsies for Active Surveillance for Prostate Cancer? Results from the PRIAS Study

C. Marenghi, Sebastiaan Remmers, Monique J. Roobol, Karl H. Tully, Mikio Sugimoto, Frédéric Staerman, Jeroen J. Lodder, F. Lozano-Urunuela, Markus Graefen, Diederik Somford, Philipp Papavassilis, Antti Rannikko, Roderick C.N. van den Bergh
article en

Abstract

Background and objective This study evaluated the added value of systematic biopsies (SBx) in addition to targeted biopsies (TBx) for detecting upgrading during repeat biopsies on active surveillance (AS) using data from the Prostate Cancer Research International Active Surveillance study. Methods We analyzed repeat biopsies of men who underwent magnetic resonance imaging (MRI) and SBx at diagnosis, with or without TBx depending on the presence of an MRI lesion, had at least one positive (Prostate Imaging Reporting and Data System 3–5) follow-up MRI, and received both SBx + TBx at subsequent repeat biopsy. Upgrading compared with diagnostic biopsy was assessed for TBx only, SBx only, and both, using three definitions: any upgrading, upgrading to grade group (GG) ≥2 with cribriform growth or intraductal carcinoma (≥GG2+), and upgrading to ≥GG3. Cumulative incidences were calculated using each detection method as competing events. For upgrading ≥GG2+ detected by SBx only, the laterality relative to the MRI lesion was determined. Key findings and limitations We analyzed 650 repeat biopsies in 568 patients with a median follow-up of 3.0 yr (interquartile range = 1.8–4.3) for men still on AS. During available follow-up, any upgrading occurred in 238 biopsies (37%), of which 47 (7.2%) were detected by SBx only. Upgrading to ≥GG2+ and ≥GG3 was observed in 100 biopsies (16%) and 78 biopsies (12%), respectively, with SBx alone identifying 19 (3.0%) and 15 (2.3%) of these patients. At 6 yr, the cumulative incidence of ≥GG2+ upgrading was 27% (95% confidence interval [CI] = 21–32%), with 5.4% (95% CI = 2.9–9.1%) for upgrading detected exclusively by SBx. Three of the 19 cases with upgrading to ≥GG2+ detected by SBx only were located contralateral to the MRI lesion (0.5% of all biopsies). Limitations include the retrospective design, which may introduce selection and registration biases. Conclusions and clinical implications In men on AS who underwent diagnostic MRI with SBx (with or without TBx) and a positive follow-up MRI, SBx has limited added value during repeat biopsies, particularly for contralateral sampling, supporting a targeted and perilesional biopsy approach.

European Urology Open ScienceVol. 94
Universität Hamburg (DE), Kagawa University (JP), Helsinki University Hospital (FI), Erasmus MC (NL), Universitätsklinik Marien Hospital Herne (DE), Complejo Hospitalario de Navarra (ES), University Hospital Münster (DE), University Medical Center Hamburg-Eppendorf (DE), Martini-Klinik (DE), Canisius-Wilhelmina Ziekenhuis (NL), Kagawa University Hospital (JP), Erasmus MC Cancer Institute (NL), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Universidad de Navarra (ES)
Openalex Percentile: Top 13%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.